Abstract:
In the context of poor access to antiretroviral therapies in sub-Saharan Africa, the minimum treatment package intended to treat
opportunistic infections common with HIV infection is inadequate but appealing, since it presumes universal coverage of medical
care for patients living with HIV and AIDS. The overall objective of this study was to analyse the challenges which family caregivers
encountered in home-based care when they tried to access medical treatment for home-based AIDS patients in the context of
confidentiality and limited medical care. A qualitative study using in-depth interviews with a sample of 21 family caregivers - 16
females and 5 males aged between 23 and 85 years was conducted with the assistance of health personnel in two hospitals in Lesotho. Using the concept of continuity of care, this article discusses the experiences of family caregivers about home care, including their experiences of adherence to confidentiality by health care professionals and non-disclosure of AIDS as the context of illness, the circumstances under which the caregivers initiated caregiving and sought medical care, and how these factors could be stressors in caregiving. There was continuity of care where the caregivers obtained hospital support. However, when confidentiality was adhered to the caregivers were frustrated by lack of information, disrupted treatment, exclusion of their perspectives in medical care, failure to secure hospitalisation, ambiguous goals and non-responsiveness, so that continuity of care was jeopardised. Thus it can be concluded that professional-assisted disclosure benefited the patients because it facilitated continuity of care through the caregivers.
Reference:
If you would like to obtain a copy of this Research Output, please contact the Research Outputs curators at researchoutputs@hsrc.ac.za
Attribution-NonCommercial
CC BY-NC
This license lets others remix, adapt, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.